SCHEMBL15811778

SCHEMBL15811778

O=C(Nc1csc(-c2nncn2C2CC2)n1)c1cc(-n2cnc(C3CC3)c2)c(N2CCOCC2)cn1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
MAP3K5 Q99683 20/20 1.00
AKT1 P31749 13/20 0.95

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16818067 0.97 MAP3K5 (1.00) MAP3K5AKT1
SCHEMBL15823814 0.94 MAP3K5 (0.90) MAP3K5AKT1
SCHEMBL16818025 0.94 MAP3K5 (1.00) MAP3K5AKT1
SCHEMBL16818077 0.94 MAP3K5 (1.00) MAP3K5AKT1
SCHEMBL15811892 0.94 MAP3K5 (1.00) MAP3K5AKT1
SCHEMBL15811987 0.94 MAP3K5 (1.00) MAP3K5AKT1
SCHEMBL15812002 0.93 MAP3K5 (1.00) MAP3K5AKT1
SCHEMBL16818085 0.92 MAP3K5 (1.00) MAP3K5AKT1
SCHEMBL16818028 0.92 MAP3K5 (1.00) MAP3K5AKT1
SCHEMBL15811812 0.91 MAP3K5 (1.00) MAP3K5AKT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9943521-B2 Apoptosis signal-regulating kinase inhibitors GILEAD SCIENCES, INC. (US) 2018-04-17 US claimed
US-20170173031-A1 APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS GILEAD SCIENCES, INC. 2017-06-22 US claimed
EP-3150597-A1 SUBSTITUTED PYRIDINE-2-CARBOXAMIDE COMPOUNDS AS APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS Gilead Sciences, Inc. (US) 2017-04-05 EP claimed
EP-2935258-B1 SUBSTITUTED PYRIDINE-2-CARBOXAMIDE COMPOUNDS AS APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS GILEAD SCIENCES INC (US) 2016-11-02 EP claimed
EP-2935258-A1 SUBSTITUTED PYRIDINE-2-CARBOXAMIDE COMPOUNDS AS APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS Gilead Sciences, Inc. (US) 2015-10-28 EP claimed
US-20150246910-A1 APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS GILEAD SCIENCES, INC. 2015-09-03 US claimed
US-9051313-B2 Apoptosis signal-regulating kinase inhibitors GILDEAD SCIENCES, INC. (US) 2015-06-09 US claimed
US-20140179663-A1 APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS GILEAD SCIENCES, INC. (US) 2014-06-26 US claimed
WO-2014100541-A1 SUBSTITUTED PYRIDINE-2-CARBOXAMIDE COMPOUNDS AS APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS GILEAD SCIENCES, INC. (US) 2014-06-26 WO claimed
US-10307427-B2 Apoptosis signal-regulating kinase inhibitors GILEAD SCIENCES, INC. (US) 2019-06-04 US disclosed
US-10307427-B2 Apoptosis signal-regulating kinase inhibitors GILEAD SCIENCES, INC. (US) 2019-06-04 US disclosed
US-20180303844-A1 APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS GILEAD SCIENCES, INC. 2018-10-25 US disclosed
US-9943521-B2 Apoptosis signal-regulating kinase inhibitors GILEAD SCIENCES, INC. (US) 2018-04-17 US disclosed
US-9943521-B2 Apoptosis signal-regulating kinase inhibitors GILEAD SCIENCES, INC. (US) 2018-04-17 US disclosed
US-9051313-B2 Apoptosis signal-regulating kinase inhibitors GILDEAD SCIENCES, INC. (US) 2015-06-09 US disclosed
US-20140179663-A1 APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS GILEAD SCIENCES, INC. (US) 2014-06-26 US disclosed
US-20140179663-A1 APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS GILEAD SCIENCES, INC. (US) 2014-06-26 US disclosed
US-20140179663-A1 APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS GILEAD SCIENCES, INC. (US) 2014-06-26 US disclosed
WO-2014100541-A1 SUBSTITUTED PYRIDINE-2-CARBOXAMIDE COMPOUNDS AS APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS GILEAD SCIENCES, INC. (US) 2014-06-26 WO disclosed
WO-2014100541-A1 SUBSTITUTED PYRIDINE-2-CARBOXAMIDE COMPOUNDS AS APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS GILEAD SCIENCES, INC. (US) 2014-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10307427-B2 Apoptosis signal-regulating kinase inhibitors AIFM1, DAPK1, MAP3K1 MAP3K5 12/4885AKT1 311/4885
US-20140179663-A1 APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS AIFM1, MAP3K1, DAPK1 MAP3K5 12/4885AKT1 368/4885
US-20150246910-A1 APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS AIFM1, MAP3K1, DAPK1 MAP3K5 12/4885AKT1 368/4885
US-20180303844-A1 APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS AIFM1, DAPK1, MAP3K1 MAP3K5 12/4885AKT1 311/4885
US-20170173031-A1 APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS AIFM1, MAP3K1, DAPK1 MAP3K5 12/4885AKT1 368/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.